SE9301830D0
(sv)
*
|
1993-05-28 |
1993-05-28 |
Ab Astra |
New compounds
|
US6875872B1
(en)
*
|
1993-05-28 |
2005-04-05 |
Astrazeneca |
Compounds
|
US5877192A
(en)
*
|
1993-05-28 |
1999-03-02 |
Astra Aktiebolag |
Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
|
ATE206044T1
(de)
|
1994-07-08 |
2001-10-15 |
Astrazeneca Ab |
Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
|
SE504459C2
(sv)
*
|
1994-07-15 |
1997-02-17 |
Astra Ab |
Förfarande för framställning av substituerade sulfoxider
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9500478D0
(sv)
*
|
1995-02-09 |
1995-02-09 |
Astra Ab |
New pharmaceutical formulation and process
|
HRP960232A2
(en)
*
|
1995-07-03 |
1998-02-28 |
Astra Ab |
A process for the optical purification of compounds
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6699885B2
(en)
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US6489346B1
(en)
*
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US6645988B2
(en)
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE508669C2
(sv)
*
|
1996-04-26 |
1998-10-26 |
Astra Ab |
Nytt förfarande
|
SE510666C2
(sv)
*
|
1996-12-20 |
1999-06-14 |
Astra Ab |
Nya Kristallmodifikationer
|
SE9702000D0
(sv)
*
|
1997-05-28 |
1997-05-28 |
Astra Ab |
New pharmaceutical formulation
|
US6747155B2
(en)
|
1997-05-30 |
2004-06-08 |
Astrazeneca Ab |
Process
|
SE510650C2
(sv)
*
|
1997-05-30 |
1999-06-14 |
Astra Ab |
Ny förening
|
SE510643C2
(sv)
*
|
1997-06-27 |
1999-06-14 |
Astra Ab |
Termodynamiskt stabil omeprazol natrium form B
|
US6096340A
(en)
*
|
1997-11-14 |
2000-08-01 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
US6174548B1
(en)
|
1998-08-28 |
2001-01-16 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
ATE500815T1
(de)
*
|
1997-12-08 |
2011-03-15 |
Dietrich Rango |
Neue suppositoriumsform mit säureempfindlichem wirkstoff
|
SE9704869D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulaton II
|
SE9704870D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulation I
|
US20020039597A1
(en)
*
|
1998-04-20 |
2002-04-04 |
Koji Ukai |
Stabilized compositions containing benzimidazole-type compounds
|
CN100396675C
(zh)
|
1998-08-10 |
2008-06-25 |
加利福尼亚州大学董事会 |
质子泵抑制剂的前药
|
US6733778B1
(en)
|
1999-08-27 |
2004-05-11 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
SE9803772D0
(sv)
|
1998-11-05 |
1998-11-05 |
Astra Ab |
Pharmaceutical formulation
|
DK1131316T3
(da)
|
1998-11-18 |
2004-09-27 |
Astrazeneca Ab |
Forbedret kemisk fremgangsmåde og farmaceutisk præparat
|
SE9900274D0
(sv)
*
|
1999-01-28 |
1999-01-28 |
Astra Ab |
New compound
|
US6852739B1
(en)
*
|
1999-02-26 |
2005-02-08 |
Nitromed Inc. |
Methods using proton pump inhibitors and nitric oxide donors
|
TWI243672B
(en)
|
1999-06-01 |
2005-11-21 |
Astrazeneca Ab |
New use of compounds as antibacterial agents
|
JP2003501488A
(ja)
*
|
1999-06-11 |
2003-01-14 |
ネオルックス コーポレイション |
骨髄抑制のための高投与量放射性核種錯体
|
US7094885B2
(en)
*
|
1999-07-11 |
2006-08-22 |
Neorx Corporation |
Skeletal-targeted radiation to treat bone-associated pathologies
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6262086B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6268385B1
(en)
|
1999-08-26 |
2001-07-31 |
Robert R. Whittle |
Dry blend pharmaceutical formulations
|
US6312712B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Method of improving bioavailability
|
US6262085B1
(en)
*
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6326384B1
(en)
|
1999-08-26 |
2001-12-04 |
Robert R. Whittle |
Dry blend pharmaceutical unit dosage form
|
US6316020B1
(en)
|
1999-08-26 |
2001-11-13 |
Robert R. Whittle |
Pharmaceutical formulations
|
EP1595879A3
(en)
*
|
1999-08-26 |
2010-01-27 |
aaiPharma Inc. |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6312723B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6780880B1
(en)
|
1999-08-26 |
2004-08-24 |
Robert R. Whittle |
FT-Raman spectroscopic measurement
|
DE60016617T2
(de)
*
|
1999-10-01 |
2005-04-28 |
Natco Pharma Ltd., Banjara Hills |
Magensaftresistente gelartige weichkapsel
|
KR20020038759A
(ko)
*
|
1999-10-20 |
2002-05-23 |
다니구치 미즈오 |
벤즈이미다졸계 화합물 안정화 방법
|
SE9903831D0
(sv)
|
1999-10-22 |
1999-10-22 |
Astra Ab |
Formulation of substituted benzimidazoles
|
DE60015607T2
(de)
|
2000-02-24 |
2005-11-10 |
Kopran Research Laboratories Ltd. |
Oral verabreichbare säurebeständige geschwürbehandelnde benzimidazolderivate
|
SE0000774D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
WO2001087831A2
(en)
*
|
2000-05-15 |
2001-11-22 |
Ranbaxy Laboratories Limited |
Novel amorphous form of omeprazole salts
|
US6306435B1
(en)
*
|
2000-06-26 |
2001-10-23 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
|
JP5412023B2
(ja)
|
2000-08-04 |
2014-02-12 |
武田薬品工業株式会社 |
ベンズイミダゾール化合物の塩およびその用途
|
CA2386716C
(en)
*
|
2002-05-17 |
2012-07-24 |
Bernard Charles Sherman |
Magnesium salt of s-omeprazole
|
AU2003204233B8
(en)
*
|
2000-08-04 |
2008-06-26 |
Bernard Charles Sherman |
Magnesium salt of S-omeprazole
|
US6544556B1
(en)
|
2000-09-11 |
2003-04-08 |
Andrx Corporation |
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
US20020064555A1
(en)
*
|
2000-09-29 |
2002-05-30 |
Dan Cullen |
Proton pump inhibitor formulation
|
AU2002249935A1
(en)
|
2001-01-08 |
2002-08-19 |
Neorx Corporation |
Radioactively labelled conjugates of phosphonates
|
WO2002083608A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Apsinterm Llc |
Methods of preparing sulfinamide and sulfoxides
|
SE0101379D0
(sv)
|
2001-04-18 |
2001-04-18 |
Diabact Ab |
Komposition som hämmar utsöndring av magsyra
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
GB2376231A
(en)
*
|
2001-06-06 |
2002-12-11 |
Cipla Ltd |
Benzimidazole-cyclodextrin inclusion complex
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
CA2445513A1
(en)
|
2001-09-18 |
2003-03-27 |
Zeria Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
US20040006111A1
(en)
*
|
2002-01-25 |
2004-01-08 |
Kenneth Widder |
Transmucosal delivery of proton pump inhibitors
|
WO2003074514A1
(en)
*
|
2002-03-05 |
2003-09-12 |
Astrazeneca Ab |
Alkylammonium salts of omeprazole and esomeprazole
|
ES2320438T7
(es)
|
2002-04-09 |
2013-02-14 |
Flamel Technologies |
Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
|
US6894066B2
(en)
*
|
2002-05-09 |
2005-05-17 |
Bernard Charles Sherman |
Magnesium salt of S-omeprazole
|
RU2292342C2
(ru)
*
|
2002-07-19 |
2007-01-27 |
Уинстон Фармасьютикалс ЛЛС. |
Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
|
TW200410955A
(en)
*
|
2002-07-29 |
2004-07-01 |
Altana Pharma Ag |
Novel salt of (S)-PANTOPRAZOLE
|
US7211590B2
(en)
*
|
2002-08-01 |
2007-05-01 |
Nitromed, Inc. |
Nitrosated proton pump inhibitors, compositions and methods of use
|
WO2004020436A1
(en)
|
2002-08-30 |
2004-03-11 |
Reddy's Laboratories Limited |
Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
|
ES2534713T3
(es)
|
2002-10-16 |
2015-04-27 |
Takeda Pharmaceutical Company Limited |
Preparaciones sólidas estables
|
SE0203065D0
(sv)
|
2002-10-16 |
2002-10-16 |
Diabact Ab |
Gastric acid secretion inhibiting composition
|
US20040235903A1
(en)
*
|
2002-10-22 |
2004-11-25 |
Khanna Mahavir Singh |
Amorphous form of esomeprazole salts
|
WO2004046134A2
(en)
*
|
2002-11-18 |
2004-06-03 |
Dr. Reddy's Laboratories Limited |
Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
|
DE10254167A1
(de)
|
2002-11-20 |
2004-06-09 |
Icon Genetics Ag |
Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
|
US7301030B2
(en)
|
2002-12-06 |
2007-11-27 |
Nycomed Gmbh |
Process for preparing (S)-pantoprazole
|
RS52667B
(en)
|
2002-12-06 |
2013-06-28 |
Nycomed Gmbh |
PROCEDURE FOR PREPARING OPTICALLY CLEAN UNITS
|
FR2848555B1
(fr)
|
2002-12-16 |
2006-07-28 |
Negma Gild |
Enantiomere(-)du tenatoprazole et son application en therapeutique
|
US20040166162A1
(en)
*
|
2003-01-24 |
2004-08-26 |
Robert Niecestro |
Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
|
US20040248942A1
(en)
*
|
2003-02-20 |
2004-12-09 |
Bonnie Hepburn |
Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
|
EP1606279A1
(en)
*
|
2003-02-28 |
2005-12-21 |
Ranbaxy Laboratories, Ltd. |
Polymorphs of s-omeprazole
|
WO2004089935A1
(en)
*
|
2003-04-10 |
2004-10-21 |
Hetero Drugs Limitd |
Novel crystalline forms of s-omeprazole magnesium
|
EP1633736A1
(en)
*
|
2003-05-05 |
2006-03-15 |
Ranbaxy Laboratories Limited |
Barium salt of benzimidazole derivative
|
WO2004099182A1
(en)
*
|
2003-05-05 |
2004-11-18 |
Ranbaxy Laboratories Limited |
Zinc salt of (s)-omeprazole
|
WO2005016917A1
(en)
*
|
2003-07-15 |
2005-02-24 |
Allergan, Inc. |
Process for preparing isomerically pure prodrugs of proton pump inhibitors
|
US20050037070A1
(en)
*
|
2003-07-18 |
2005-02-17 |
Santarus, Inc. |
Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
JP2006528182A
(ja)
*
|
2003-07-18 |
2006-12-14 |
サンタラス インコーポレイティッド |
薬学的製剤および酸に起因する消化器疾患の治療法
|
CN100457104C
(zh)
*
|
2003-07-23 |
2009-02-04 |
尼科梅德有限责任公司 |
质子泵抑制剂的碱性盐
|
PT1651217E
(pt)
*
|
2003-07-23 |
2008-05-23 |
Nycomed Gmbh |
Sais alcalinos de inibidores da bomba de protões
|
WO2005011637A1
(ja)
*
|
2003-08-04 |
2005-02-10 |
Eisai Co., Ltd. |
用時分散型製剤
|
SE0302381D0
(sv)
|
2003-09-04 |
2003-09-04 |
Astrazeneca Ab |
New salts I
|
SE0302382D0
(sv)
*
|
2003-09-04 |
2003-09-04 |
Astrazeneca Ab |
New salts II
|
WO2005027880A1
(en)
*
|
2003-09-25 |
2005-03-31 |
Natco Pharma Limited |
Enteric soft gelatin capsule containing esomeprazole and method of preparation
|
MXPA06003450A
(es)
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Recubrimiento de farmaco que proporciona alta carga del farmaco y metodos para proporcionar el mismo.
|
US20050075371A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Allergan, Inc. |
Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
|
AU2003272086A1
(en)
*
|
2003-10-14 |
2005-04-27 |
Natco Pharma Limited |
Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
|
GB0403165D0
(en)
*
|
2004-02-12 |
2004-03-17 |
Ct |
Novel uses for proton pump inhibitors
|
AU2005216862A1
(en)
*
|
2004-02-18 |
2005-09-09 |
Allergan, Inc. |
Compositions comprising prodrugs of proton pump inhibitors
|
JP2007523164A
(ja)
*
|
2004-02-18 |
2007-08-16 |
アラーガン、インコーポレイテッド |
プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
|
SE0400410D0
(sv)
|
2004-02-20 |
2004-02-20 |
Astrazeneca Ab |
New compounds
|
WO2005082888A1
(en)
*
|
2004-03-01 |
2005-09-09 |
Milen Merkez Ilac Endustrisi A.S. |
Process for the preparation of magnesium salt of omeprazole
|
DE602004022337D1
(de)
|
2004-04-28 |
2009-09-10 |
Hetero Drugs Ltd |
Verfahren zur herstellung von pyridinylmethyl-1h-benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
DK1748998T3
(da)
*
|
2004-05-28 |
2010-05-10 |
Hetero Drugs Ltd |
Ny stereoselektiv syntese af benzimidazolsulfoxider
|
US20050267159A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Aaipharma, Inc. |
Magnesium complexes of S-omeprazole
|
US20050267157A1
(en)
*
|
2004-05-28 |
2005-12-01 |
David White |
Magnesium-S-omeprazole
|
EP1765806A1
(en)
*
|
2004-06-24 |
2007-03-28 |
AstraZeneca AB |
New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
|
WO2006001755A1
(en)
*
|
2004-06-24 |
2006-01-05 |
Astrazeneca Ab |
A new esomeprazole sodium salt crystal modification
|
US20060024362A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Pawan Seth |
Composition comprising a benzimidazole and process for its manufacture
|
KR100847635B1
(ko)
*
|
2004-08-06 |
2008-07-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
벤즈이미다졸 유도체와 아민과의 염
|
JP3921497B2
(ja)
|
2004-08-06 |
2007-05-30 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ベンズイミダゾール誘導体とアミンとの塩およびその製造方法
|
US8541026B2
(en)
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
EP1830822A1
(en)
*
|
2004-12-24 |
2007-09-12 |
LEK Pharmaceuticals D.D. |
Stable pharmaceutical composition comprising an active substance in the form of solid solution
|
US20060160783A1
(en)
*
|
2004-12-30 |
2006-07-20 |
Transform Pharmaceuticals, Inc. |
Novel omeprazole forms and related methods
|
ES2259269B1
(es)
|
2005-03-03 |
2007-11-01 |
Esteve Quimica, S.A. |
Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
|
ES2375298T3
(es)
|
2005-03-25 |
2012-02-28 |
Livzon Pharmaceutical Group Inc. |
Procedimiento para preparar derivados de sulfóxido sustituidos.
|
EP1885711A1
(en)
|
2005-05-06 |
2008-02-13 |
Glenmark Pharmaceuticals Limited |
Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
|
WO2006121995A2
(en)
*
|
2005-05-09 |
2006-11-16 |
Tap Pharmaceutical Products, Inc. |
Methods for treating nephrolithiasis
|
US7803817B2
(en)
|
2005-05-11 |
2010-09-28 |
Vecta, Ltd. |
Composition and methods for inhibiting gastric acid secretion
|
US7981908B2
(en)
|
2005-05-11 |
2011-07-19 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion
|
EP1891043A1
(en)
*
|
2005-06-15 |
2008-02-27 |
Hetero Drugs Limited |
Amorphous esomeprazole hydrate
|
KR100641534B1
(ko)
|
2005-07-28 |
2006-11-01 |
한미약품 주식회사 |
에스오메프라졸 및 그의 염의 제조방법
|
CA2617248C
(en)
*
|
2005-08-03 |
2015-09-29 |
Tap Pharmaceutical Products, Inc. |
Methods for treating hypertension
|
US20070043085A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of amorphous form of neutral esomeprazole
|
WO2007031845A2
(en)
*
|
2005-09-14 |
2007-03-22 |
Glenmark Pharmaceuticals Limited |
Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
|
BRPI0617987A2
(pt)
*
|
2005-10-06 |
2011-08-16 |
Auspex Pharmaceuticals Inc |
composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
|
US7576219B2
(en)
|
2005-10-26 |
2009-08-18 |
Hanmi Pharm. Co., Ltd |
Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
|
US8124779B2
(en)
|
2005-12-05 |
2012-02-28 |
Astrazeneca Ab |
Process for the preparation of esomeprazole non-salt form
|
EP1801110A1
(en)
|
2005-12-22 |
2007-06-27 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Esomeprazole arginine salt
|
US7553857B2
(en)
|
2005-12-23 |
2009-06-30 |
Lek Pharmaceuticals D.D. |
S-omeprazole magnesium
|
ES2325336T3
(es)
*
|
2005-12-28 |
2009-09-01 |
Union Quimico-Farmaceutica, S.A. |
Procedimiento para la preparacion del enantiomero (s) de omeprazol.
|
US8063074B2
(en)
|
2006-05-04 |
2011-11-22 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of esomeprazole sodium
|
JP2009539830A
(ja)
*
|
2006-06-07 |
2009-11-19 |
アストラゼネカ・アクチエボラーグ |
エソメプラゾールのアンモニウム塩の新規な製造方法
|
US7863330B2
(en)
*
|
2006-06-14 |
2011-01-04 |
Rottapharm S.P.A. |
Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
|
WO2008004245A1
(en)
|
2006-07-05 |
2008-01-10 |
Lupin Limited |
Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
|
US9233092B2
(en)
|
2006-07-25 |
2016-01-12 |
Vecta, Ltd. |
Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
|
US20100317689A1
(en)
*
|
2006-09-19 |
2010-12-16 |
Garst Michael E |
Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
|
GB2459393B
(en)
|
2006-10-05 |
2010-09-08 |
Santarus Inc |
Novel capsule formulation for the proton pump inhibitor omeprazole
|
US20090092658A1
(en)
*
|
2007-10-05 |
2009-04-09 |
Santarus, Inc. |
Novel formulations of proton pump inhibitors and methods of using these formulations
|
MX2009004475A
(es)
|
2006-10-27 |
2009-08-12 |
Univ Missouri |
Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
|
BRPI0718611A2
(pt)
*
|
2006-11-13 |
2014-02-25 |
Takeda Pharmaceuticals North America Inc |
Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
|
US20090124623A1
(en)
*
|
2006-11-13 |
2009-05-14 |
Christopher Lademacher |
Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
|
EP1947099A1
(en)
|
2007-01-18 |
2008-07-23 |
LEK Pharmaceuticals D.D. |
Process for solvent removal from omeprazole salts
|
EP2120956A4
(en)
*
|
2007-01-19 |
2010-01-20 |
Takeda Pharmaceuticals North A |
METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
|
EP2114919A2
(en)
*
|
2007-01-31 |
2009-11-11 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
WO2008102145A2
(en)
|
2007-02-21 |
2008-08-28 |
Cipla Limited |
Process for the preparation of esomeprazole magnesium dihydrate
|
KR101303813B1
(ko)
*
|
2007-04-16 |
2013-09-04 |
에스케이케미칼주식회사 |
라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
|
EP2000468A1
(en)
*
|
2007-05-09 |
2008-12-10 |
Dr. Reddy's Laboratories Ltd. |
Esomeprazole salts and processes for preparation thereof
|
ATE534643T1
(de)
*
|
2007-06-07 |
2011-12-15 |
Aurobindo Pharma Ltd |
Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
|
CN101323609B
(zh)
*
|
2007-06-15 |
2013-05-01 |
成都福瑞生物工程有限公司 |
不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
|
US7947840B2
(en)
|
2007-09-25 |
2011-05-24 |
Hetero Drugs Limited |
Process for preparation of enantiomerically pure esomeprazole
|
WO2009047775A2
(en)
*
|
2007-10-08 |
2009-04-16 |
Hetero Drugs Limited |
Polymorphs of esomeprazole salts
|
FR2925899B1
(fr)
*
|
2007-12-27 |
2012-12-21 |
Sidem Pharma Sa |
Procede de preparation enantioselective de sulfoxydes.
|
US8247440B2
(en)
|
2008-02-20 |
2012-08-21 |
Curators Of The University Of Missouri |
Composition comprising omeprazole, lansoprazole and at least one buffering agent
|
US20090280173A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Ishwar Chauhan |
Multilayer Omeprazole Tablets
|
US20090280175A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Ishwar Chauhan |
Multilayer Proton Pump Inhibitor Tablets
|
WO2009145368A1
(en)
*
|
2008-05-27 |
2009-12-03 |
Sk Chemicals Co., Ltd. |
Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
|
EP2143722A1
(en)
*
|
2008-07-09 |
2010-01-13 |
Lek Pharmaceuticals D.D. |
Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
|
EP2147918A1
(en)
|
2008-07-21 |
2010-01-27 |
LEK Pharmaceuticals D.D. |
Process for the preparation of S-omeprazole magnesium in a stable form
|
AU2009290712A1
(en)
|
2008-09-09 |
2010-03-18 |
Astrazeneca Ab |
Method for delivering a pharmaceutical composition to patient in need thereof
|
EP2264024A1
(en)
|
2008-10-14 |
2010-12-22 |
LEK Pharmaceuticals d.d. |
Process for the preparation of enantiomerically enriched proton pump inhibitors
|
WO2010058409A2
(en)
|
2008-11-18 |
2010-05-27 |
Hetero Research Foundation |
Optical purification of esomeprazole
|
US20100311756A1
(en)
*
|
2009-01-22 |
2010-12-09 |
Takeda Pharmaceuticals North America, Inc. |
Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
|
WO2010097583A1
(en)
|
2009-02-24 |
2010-09-02 |
Cipla Limited |
Esomeprazole potassium polymorph and its preparation
|
WO2010151697A1
(en)
*
|
2009-06-25 |
2010-12-29 |
Pozen Inc. |
Method for treating a patient in need of aspirin therapy
|
JP2012531409A
(ja)
|
2009-06-25 |
2012-12-10 |
アストラゼネカ・アクチエボラーグ |
Nsaid関連潰瘍を発症するリスクがある患者の処置方法
|
EP2319504A1
(en)
|
2009-11-07 |
2011-05-11 |
Laboratorios Del. Dr. Esteve, S.A. |
Pharmaceutical solid dosage form
|
US8748619B2
(en)
|
2009-11-12 |
2014-06-10 |
Hetero Research Foundation |
Process for the resolution of omeprazole
|
US20120294937A1
(en)
|
2009-12-29 |
2012-11-22 |
Novartis Ag |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
WO2011080500A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
EP2345408A3
(en)
|
2010-01-08 |
2012-02-29 |
Dr. Reddy's Laboratories Ltd. |
Acid labile drug formulations
|
JP5714031B2
(ja)
|
2010-02-12 |
2015-05-07 |
エステヴェ キミカ, エス.エー. |
エソメプラゾールナトリウムのナトリウム塩の調製方法
|
US20110207779A1
(en)
*
|
2010-02-25 |
2011-08-25 |
Glenmark Generics Ltd |
Process for the preparation of esomeprazole magnesium
|
CA2812034C
(en)
|
2010-09-10 |
2018-10-23 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for concomitant treatment of theophylline and febuxostat
|
CN102816149B
(zh)
*
|
2011-06-10 |
2015-05-13 |
上海汇伦生命科技有限公司 |
一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
|
CN102807561A
(zh)
*
|
2011-06-21 |
2012-12-05 |
寿光富康制药有限公司 |
S-奥美拉唑铝盐及其制备方法和应用
|
CN102850323A
(zh)
*
|
2011-06-30 |
2013-01-02 |
秦引林 |
一种埃索美拉唑钠的精制方法
|
CN102321071B
(zh)
*
|
2011-07-20 |
2013-01-23 |
江苏奥赛康药业股份有限公司 |
一种高纯度埃索美拉唑钠的工业化生产方法
|
CN104844577A
(zh)
*
|
2011-07-31 |
2015-08-19 |
连云港润众制药有限公司 |
埃索美拉唑镁的晶型
|
WO2013081566A1
(en)
|
2011-11-25 |
2013-06-06 |
Mahmut Bilgic |
A formulation comprising benzimidazole
|
EP2601947A1
(en)
|
2011-12-05 |
2013-06-12 |
Abo Bakr Mohammed Ali Al-Mehdar |
Fixed-dose combination for treatment of helicobacter pylori associated diseases
|
WO2013088109A1
(en)
|
2011-12-16 |
2013-06-20 |
Oxagen Limited |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
BR112014016085A8
(pt)
|
2011-12-28 |
2017-07-04 |
Pozen Inc |
composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
|
CN104203938A
(zh)
|
2012-01-21 |
2014-12-10 |
朱比兰特生命科学有限公司 |
用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
|
CN103420978A
(zh)
*
|
2012-05-15 |
2013-12-04 |
上海医药工业研究院 |
一种苯并咪唑类化合物的镁盐的制备方法
|
CN102657622A
(zh)
*
|
2012-05-17 |
2012-09-12 |
康普药业股份有限公司 |
一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
|
CN102964335B
(zh)
*
|
2012-11-13 |
2014-06-25 |
凌元敏 |
一种埃索美拉唑钠化合物及其制备方法和用途
|
CN103159737B
(zh)
*
|
2013-04-12 |
2014-03-19 |
四川省惠达药业有限公司 |
一种埃索美拉唑钠化合物及药物组合物
|
WO2015065848A1
(en)
|
2013-11-04 |
2015-05-07 |
Capsugel Belgium Nv |
Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
|
EP2929885A1
(en)
|
2014-04-11 |
2015-10-14 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
EP2933002A1
(en)
|
2014-04-11 |
2015-10-21 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
CN104045627A
(zh)
*
|
2014-05-21 |
2014-09-17 |
丽珠医药集团股份有限公司 |
一种奥美拉唑纯化方法
|
CN104530003A
(zh)
*
|
2014-06-10 |
2015-04-22 |
广东东阳光药业有限公司 |
吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
|
EP2980086B1
(en)
|
2014-07-29 |
2016-06-15 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Efficient process for the preparation of esomeprazole (S)-binol complex
|
US10307748B2
(en)
|
2014-12-26 |
2019-06-04 |
The University Of Tokyo |
Method for producing proton pump inhibitor compound having optical activity
|
EP3064495B1
(en)
|
2015-03-06 |
2016-12-14 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of optically pure esomeprazole
|
WO2017145146A1
(en)
|
2016-02-25 |
2017-08-31 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising proton pump inhibitors
|
CN105924430A
(zh)
*
|
2016-06-27 |
2016-09-07 |
杭州富阳伟文环保科技有限公司 |
一种埃索美拉唑钠的精制方法
|
US10939686B2
(en)
*
|
2017-04-11 |
2021-03-09 |
Mclaughlin Gormley King Company |
Sabadilla oil and uses thereof
|
CN108409714A
(zh)
*
|
2018-03-29 |
2018-08-17 |
成都通德药业有限公司 |
埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
|
JP2022541438A
(ja)
*
|
2019-07-16 |
2022-09-26 |
キンドレッド バイオサイエンシズ インコーポレイテッド |
ウマ科動物用エソメプラゾール製剤及び使用方法
|
JP7335002B2
(ja)
|
2019-08-29 |
2023-08-29 |
学校法人東京理科大学 |
スルホキシド化合物のエナンチオマー調製方法及びエナンチオマー調製システム
|
RU2726320C1
(ru)
*
|
2020-02-09 |
2020-07-13 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) |
Способ определения примесных компонентов омепразола
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|